Inovio Pharmaceuticals Q3 2025 Earnings Preview

* Inovio Pharmaceuticals (INO [https://seekingalpha.com/symbol/INO]) is scheduled to announce Q3 earnings results on Monday, November 10th, after market close.
* The consensus EPS Estimate is -$0.48 [https://seekingalpha.com/symbol/INO/earnings/estimates] (+46.1% Y/Y)Over the last 2 years, INO has beaten EPS estimates [https://seekingalpha.com/symbol/INO/earnings/eps-surprise-summary] 50% of the time and has beaten revenue estimates 25% of the time.
* Over the last 3 months, EPS estimates have seen 4 upward revisions [https://seekingalpha.com/symbol/INO/earnings/revisions] and 1 downward. Revenue estimates have seen 0 upward revisions and 1 downward.

MORE ON INOVIO PHARMACEUTICALS

* Inovio Pharmaceuticals, Inc. (INO) Presents At H.C. Wainwright 27th Annual Global Investment Conference (Transcript) [https://seekingalpha.com/article/4819943-inovio-pharmaceuticals-inc-ino-presents-at-h-c-wainwright-27th-annual-global-investment]
* Inovio: Back On Track With INO-3107 BLA For RRP Before End Of 2025 [https://seekingalpha.com/article/4817196-inovio-back-on-track-with-ino-3107-bla-for-rrp-before-end-of-2025]
* Inovio says FDA agrees with rolling BLA submission for rare disease asset [https://seekingalpha.com/news/4489218-inovio-says-fda-agrees-rolling-bla-submission-rare-disease-asset]